Orange Book product · Generic (ANDA)
SEVELAMER CARBONATE
SEVELAMER CARBONATE
At a glance
Dec 23, 2021
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Dec 23, 2021
4 yr 7 mo ago
Today
Pharmaceutical detail
Active ingredient
SEVELAMER CARBONATE
Strength
2.4GM/PACKET
Dosage form
FOR SUSPENSION
Route
ORAL
TE code
Not listed
Application
ANDA 201513
Product number
002
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of SEVELAMER CARBONATE
- 2009RENVELABrand (NDA)
NDA 022318 · GENZYME
- 2007RENVELABrand (NDA)
NDA 022127 · SANOFI
- 2025SEVELAMER CARBONATEGeneric (ANDA)
ANDA 219931 · NAVINTA LLC
- 2025SEVELAMER CARBONATEGeneric (ANDA)
ANDA 215909 · TORRENT
- 2024SEVELAMER CARBONATEGeneric (ANDA)
ANDA 215998 · SHANDONG XINHUA
- 2024SEVELAMER CARBONATEGeneric (ANDA)
ANDA 206234 · INVAGEN PHARMS
- 2024SEVELAMER CARBONATEGeneric (ANDA)
ANDA 211915 · STRIDES PHARMA
- 2024SEVELAMER CARBONATEGeneric (ANDA)
ANDA 207291 · MACLEODS PHARMS LTD
- 2023SEVELAMER CARBONATEGeneric (ANDA)
ANDA 211917 · STRIDES PHARMA INTL
- 2023SEVELAMER CARBONATEGeneric (ANDA)
ANDA 206100 · MACLEODS PHARMS LTD
- 2023SEVELAMER CARBONATEGeneric (ANDA)
ANDA 217319 · CHARTWELL RX
- 2022SEVELAMER CARBONATEGeneric (ANDA)
ANDA 215537 · MICRO LABS
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

